A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran.
Concerning medical treatments for adult attention-deficit/hyperactivity disorder (AD/HD), case reports have gradually been accumulating on the efficacy of psychostimulants such as methylphenidate and amphetamine and selective noradrenaline reuptake inhibitors such as atomoxetine. However, patients intolerant to psychostimulants currently have a very limited range of treatments available to them. Here, we report a case of an adult AD/HD patient whose inattention and hyperactivity were remarkably alleviated by milnacipran, a serotonin noradrenaline reuptake inhibitor. Milnacipran has fewer side effects than comparable drugs, and we believe it could be developed into a good curative treatment for AD/HD in the future.
Kako
Yuki
Y
Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan. yukikako@nifty.com
Niwa
Yusuke
Y
Toyomaki
Atsuhito
A
Yamanaka
Hiroyoshi
H
Kitagawa
Nobuki
N
Denda
Kenzo
K
Koyama
Tsukasa
T
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D003521:Cyclopropanes / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000078764:Milnacipran
D000928:Antidepressive Agents; D003521:Cyclopropanes; D000078764:Milnacipran